Key Takeaways Expanded distribution and positive clinical data are set to boost adoption of Amtagvi and strengthen revenue growth in oncology markets. Operational streamlining, new pipeline advancements, and global expansion efforts are expected to improve profitability and diversify long-term earnings.Read more
Key Takeaways Faster-than-expected physician adoption, expanded patient access, and greater operating efficiency could drive revenue and profitability substantially beyond current expectations. Strong first-mover advantage, broad patent protection, and pipeline innovation position Iovance for sustained growth and long-term revenue diversification.Read more
Key Takeaways Sustained high costs, complex distribution, and slow commercialization delay profitability and threaten market share amid rising competition from newer cancer therapies. Ongoing financial challenges, including exposure to interest rates and revenue pressure from drug pricing scrutiny, heighten risk of shareholder dilution and reduced margins.Read more
Iovance Biotherapeutics, Inc., a commercial-stage biopharmaceutical company, develops and commercializes cell therapies using autologous tumor infiltrating lymphocyte for the treatment of metastatic melanoma and other solid tumor cancers in the United States. The company offers Amtagvi, a tumor-derived autologous T cell immunotherapy used to treat adult patients with unresectable or metastatic melanoma; and Proleukin, an interleukin-2 product for the treatment of patients with metastatic melanoma and metastatic renal cell carcinoma. It develops lifileucel for treatment of melanoma, cervical cancer, non-small cell lung cancer (NSCLC), endometrial cancer, and head and neck squamous cell carcinoma; IOV-2001 to treat chronic lymphocytic leukemia and small lymphocytic lymphoma; IOV-4001 for the treatment of melanoma and NSCLC; and IOV-3001, an antibody cytokine engrafted protein for use in the TIL therapy treatment regimen. The company has collaborations and licensing agreements with WuXi Advanced Therapies, Inc.; National Institutes of Health; the National Cancer Institute; H. Lee Moffitt Cancer Center; The University of Texas M.D. Anderson Cancer Center; Cellectis S.A.; Novartis Pharma AG; and Boehringer Ingelheim Biopharmaceuticals GmbH. The company was formerly known as Lion Biotechnologies, Inc. and changed its name to Iovance Biotherapeutics, Inc. in June 2017. Iovance Biotherapeutics, Inc. was incorporated in 2007 and is headquartered in San Carlos, California.
